Effects of Limited versus Standard Dose Romosozumab followed by Denosumab on Peripheral Bone Density and Microarchitecture: The LIDA-HRpQCT Extension study

Prolia (denosumab) - Amgen

Evenity (romosozumab-aqqg) - Astellas, Amgen, UCB

Benjamin Z. Leder , MD; Hang Lee , PhD; Sabashini Ramchand , MD; Joy Tsai , MD

Aug 24, 2026